ASC is developing a broad and enabling technology platform of significant clinical value. The ability to regenerate many tissues of mesodermal, ectodermal, or even endodermal origin has applications which can be used to treat diseases or trauma of cartilage, bone, muscle, connective tissues, skin, and liver, degenerative diseases, post-surgical adhesions, and congenital malformations.

ASC believes it has a sustainable competitive advantage in tisse engineering by combining the interdisciplinary approaches that apply the principles of life sciences and engineering in the development of biological substitutes that restore, maintain, or improve tissue function. ASC’s proprietary platform technology covers three interrelated fields of expertise necessary for tissue regeneration: 1) stem cells, 2) protein factors, and 3) biocompatible, biodegradable matrices to deliver stem cells and/or protein factors.


ASC has several sustainable competitive advantages using its proprietary MASCsTM over products that are currently approved or in development. The Company believes these distinct advantages over competing products will result in the Company’s products becoming the product of choice by both physicians and patients. These advantages include the following:

    The Company isolates MASCs from a donor by a skin or skeletal muscle biopsy. The MASCs are then isolated and expanded in a central facility to provide cells for all future patients. The MASCs, either in suspension or seeded into a scaffold, are then shipped to the hospital, clinic, or physician for implantation into the patient. The MASCs do not elicit an immune response and are thus not rejected by the patient even though they originally came from a non-relative donor.
    Stem cells are very rare cells in the adult. Current products or procedures use cells isolated from the patient’s blood, bone marrow, or adipose (fat) which are reinjected immediately into the same patient. This has two disadvantages: 1) the cell population are not purified stem cells, but consists of a mixture that will include differentiated cells such as fibroblasts, preadipocytes, endothelial cells, and smooth muscle cells; and 2) the number of stem cells will be in the low thousands, at best. ASC’s procedure, in contrast, purifies the MASC’s to over 95% purity and can provide millions or hundreds of millions of stem cells, depending on the clinical problem and the need.
    The Company has demonstrated that MASCs, after differentiation, have a full number of cells doublings in their life cycle as progenitor cells. Current products use the patient’s own chondrocytes and/or mesenchymal stem cells, which are limited in their ability to proliferate. The number of times autologous cells can still divide decreases with age. Thus, for older patients the autologous cells are near to cell senescence and death. Thus, the number of cells that can be generated from the patient’s own cells, particularly in patients over 50, may not be sufficient to restore the injured tissue back to normal.
  4. MASCs form the appropriate tissue types where they are implanted
    The data indicate that MASCs respond to local signals to form the cell types at the site. In articular cartilage, the MASCs form cartilage cells. In bone, the MASCs form bone cells. What is more, the MASCs can differentiate into several cell types at a site. For instance, in the presentation on the right above, where the MASCs regenerated skin, the MASCs formed keratinocytes (surface of the skin), endothelial cells and smooth muscle cells (blood vessels), hair follicle cells, and the cells of the sweat glands. Thus, the undifferentiated MASCs were able to form 5 different cell types within the skin.

Are you as excited as we are about what the future holds for stem cell therapy?
We invite you to keep up with our progress by subscribing to our newsletter.